Al-Rawi, Duaa H.
Lettera, Emanuele
Li, Jun
DiBona, Melody http://orcid.org/0000-0002-8853-2604
Bakhoum, Samuel F. http://orcid.org/0000-0002-4779-8422
Article History
Accepted: 20 June 2024
First Online: 11 July 2024
Competing interests
: S.F.B. has acted as a consultant and/or adviser of Meliora Therapeutics and Volastra Therapeutics, is a co-inventor on patents related to some of the research described in this manuscript on agents targeting chromosomal instability and the cGAS–STING pathway in patients with advanced-stage cancer (patent numbers WO2019014246A1, US20210130903A1 and EP4208572A1), and is the scientific co-founder of, holds equity in, and receives compensation from Volastra Therapeutics. The other authors declare no competing interests.